Clinical Trial Update: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating the combination of mosunetuzumab and zanubrutinib in relapsed/refractory marginal zone lymphoma. The trial is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: RECRUITING